New cancer drug enters first human trials for Tough-to-Treat tumors
NCT ID NCT06781983
Summary
This early-stage study is testing a new drug called IPH4502 in people with advanced solid tumors that have a specific protein called Nectin-4. The main goals are to find the safest dose and see how well the body handles the drug. Researchers will also look for early signs that the drug might help slow or shrink tumors in 145 participants who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Léon Bérard
RECRUITINGLyon, 69008, France
Contact
-
Gustave Roussy Cancer Institute
RECRUITINGVillejuif, 94805, France
Contact
-
John Theurer Cancer Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact
-
Massachusetts General Hospital - Boston
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
-
Mount Sinai Tisch Cancer Center
RECRUITINGNew York, New York, 10029, United States
Contact
-
NEXT Oncology - Dallas
RECRUITINGDallas, Texas, 75039, United States
Contact
-
NEXT Oncology - Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Conditions
Explore the condition pages connected to this study.